Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication.
Eleven cases of neurological defects in T-ALL patients treated with nelarabine have been described in the last 4 years, seven of these after stem cell transplantation (SCT) for T Lymphoblastic Lymphoma (T-LBL). Most of these patients had an unfavorable outcome or irreversible neurological damage. We now report the case of a 41-year-old woman suffering from T-LBL who presented with severe, but reversible myelopathy after receiving nelarabine-based treatment and mediastinal radiotherapy, and we provide a review of the literature on the topic.
Institute of Hematology, Catholic University S. Cuore, Rome.
Maria Chiara
MC
Tisi
Institute of Hematology, Catholic University S. Cuore, Rome.
Giuseppe
G
Ausoni
Institute of Neurology, Catholic University S. Cuore, Rome.
Maria Gabriella
MG
Vita
Institute of Radiology, Catholic University S. Cuore, Rome.
Tommaso
T
Tartaglione
Institute of Radiation Oncology, Catholic University S. Cuore, Rome.
Mario
M
Balducci
Institute of Hematology, Catholic University S. Cuore, Rome.
Luca
L
Laurenti
Institute of Hematology, Catholic University S. Cuore, Rome.
Patrizia
P
Chiusolo
Institute of Hematology, Catholic University S. Cuore, Rome.
Stefan
S
Hohaus
Institute of Hematology, Catholic University S. Cuore, Rome.
Simona
S
Sica